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ABSTRACT CCR5del32 Homozygous deletion  in the chemokine receptor R5 gene provides almost com-
plete protection to individuals against HIV infection. However, data relating to the protective effect for 
CCR5del32 heterozygous individuals have been contradictory. The frequency of the CCR5del32 allele in 
population control cohorts was compared with that of a group of children (27 Kalmyks and 50 Russians) 
infected by G-subtype HIV-1 in a nosocomial outbreak. The frequency of the CCR5del32 allele was shown 
to be lower among the infected children in comparison with that of the control group; however, the differ-
ence was small and statistically insignificant. Similar results were obtained in a number of earlier studies. 
The insignificance of the small differences could be a result of one of two reasons. (i) The fact that there is 
no protective effect of the heterozygous state, and that the phenomenon depends only on the fluctuation of 
allele frequencies. In this case, there would be no differences even if the infected cohort is enlarged. (ii)The 
protective effect of the heterozygous state is real; however, the size of the studied cohort is insufficient to 
demonstrate it. In order to discern between these two reasons, a meta-analysis of data from 25 published 
articles (a total of 5,963 HIV-infected individuals and 5,048 individuals in the control group, including the 
authors’ own data) was undertaken. A conclusion was drawn from the meta-analysis that the CCR5del32 al-
lele protects individuals against the HIV infection even in a heterozygous state (OR=1.22, 95%CI=1.10–1.36). 
The risk of HIV infection for CCR5 wt/del32 heterozygotes was lower by at least 13% as compared to that 
for wild type CCR5 wt/wt homozygotes. Prior to this study, no data of the type or any conclusions had been 
published for Caucasians. The mortality rate in the 15 years following the infection was found to be ap-
proximately 40% lower for CCR5del32 heterozygotes in comparison with that for the wild type homozygotes 
in the studied group. The size of the studied group was insufficient to claim difference validity (OR=2.0; p= 
0.705), even though the effect quantitatively matched the published data. The features of the meta-analysis 
influencing the threshold level and the statistical validity of the effects are being discussed. The level of the 
CCR5del32 protective effect on the chances to be infected with HIV and on the outcome of the HIV infection 
was assessed for various ethnic groups.
KEYWORDS HIV; nosocomial infection; lethality risk; infection risk; chemokine receptor gene; allele CCR5del32; 
meta-analysis.
ABBREVIATIONS HIV – human immunodeficiency virus; AIDS – acquired immune deficiency syndrome; PCR – 
polymerase chain reaction.reSeArcH ArtIcLeS
 VOL. 4  № 1 (12)  2012  | ActA nAturAe | 43
INTRODUCTION
Having started with a single case detected in 1981, the 
AIDS epidemic is now one of the most important health 
care issues both in russia and the rest of the world [1]. 
the evolution of the epidemic in russia was charac-
terized by the formation of clusters of nosocomial in-
fection that took place in 1988–1989. the outbreak of 
the infection began with a HIV-infected child at a chil-
dren hospital in elista. Antiepidemic measures were 
not taken, which resulted in the spread of the epidemic 
throughout medical institutions in Kalmykia, the ros-
tov and Volgograd districts, as well as Stavropol terri-
tory. A single focus (focus of infection) was responsible 
for infecting more than 260 children and their mothers 
[2, 3]. Many of them have long passed away (Fig. 1).
Some HIV-infected patients demonstrated rapid 
progression of the disease (2–3 years) and emergence 
of AIDS symptoms, whereas in other patients HIV 
symptoms took a considerable length of time to mani-
fest. the differences in the rate of disease progression 
may be the result of a combination of external factors 
(infection conditions, concomitant diseases, ongoing 
treatment) and the individual genetic characteristics 
of a patient [4].
Among the human genes affecting the progression 
of the HIV infection, the CCR5 gene that encodes the 
cc chemokine receptor 5, which mediates HIV binding 
to the cell membrane and penetration of certain viral 
strains into the cell, plays the most significant role [4]. 
A 32 bp deletion in the CCR5 gene (CCR5del32 (rs333)) 
results in the production of a nonfunctional protein. In-
dividuals with homozygous deletion bear no functional 
ccr5 receptors, whereas the density of these receptors 
in individuals with heterozygous deletion is reduced. 
the ccr5del32 allele occurs predominantly in euro-
pean populations. Its frequency is the highest in north-
ern european countries (up to 15–18%). It is lower than 
3–5% in most Asian populations. this allele is absent 
in almost all individuals of the native populations of 
America and Oceania [5–7].
ccr5del32 homozygous individuals (their propor-
tion in european populations is equal to 1–2%) show 
high, although not absolute, resistance to infection. 
there are very few ccr5del32 homozygous individ-
uals among HIV-infected individuals. Only 12 cases 
have been reported among the more than 20, 000 pa-
tients examined; for most of them, the virus was tropic 
for cXcr4, but not ccr5 [8–13]. the protective effect 
of CCR5del32 homozygosity has been confirmed both 
in a number of epidemiological studies (an increased 
homozygote frequency among HIV-negative individu-
als who had a risk of infection) and via in vitro infect-
ing of cD+ cells derived from individuals of various 
genotypes [14].
the protective effect of CCR5del32 heterozygos-
ity also manifested itself in the development of AIDS 
symptoms in HIV-infected individuals. It is not un-
likely that the possibility of a symptomatic undiag-
nosed bearing of HIV by ccr5del32/+ heterozygotes 
may facilitate the spread of the infection. the viral 
load in HIV-infected CCR5del32 heterozygous indi-
viduals is lower, the cD4+ t cell count decreases at 
a slower rate, and AIDS symptoms develop slower 
both in adults [8, 11, 13–17] and in children (most of 
whom were perinatally infected) [18]. the frequency 
of CCR5del32 heterozygosity was considerably higher 
in the group of individuals who were infected in the 
1980s and survived a period of 10 years post-infection 
[11].
However, data indicating that CCR5del32 heterozy-
gosity protects against HIV infection remain contro-
versial. In a number of studies, the heterozygosity fre-
quency among infected individuals has been found to 
be higher than that among the healthy ones who were 
at risk of infection, or than that of the total sample of 
the same population; points which may indicate the 
fact that individuals with the CCR5wt/del32 genotype 
have partial HIV-1 resistance [10, 12]. this has not been 
observed in other studies; the difference between the 
frequencies of CCR5wt/del32 heterozygotes and/or 
del32 alleles between groups of HIV-positive and HIV-
negative individuals have been either absent or statis-
tically insignificant [8, 19–21]. In this study, the effect 
of CCR5del32 heterozygosity on the survival rate of 
children with focus nosocomial HIV infection and the 
risk of infection upon transmission route through injec-
tion were analyzed. In addition, a meta-analysis of the 
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Fig. 1. Dynamics of the survival rate for individuals with 
nosocomial HIV infection: Russians (Rostov-on-Don – 
107, Elista – 13 individuals) and Kalmyks (Elista – 57 
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published data was performed in order to assess the po-
tential decrease in the risk of infection in heterozygous 
individuals for the CCR5del32 allele.
MATERIALS AND METHODS
Blood samples from the collection of the Biotechnology 
Laboratory (Ivanovsky Institute of Virology, russian 
Academy of Medical Sciences) were used in this study. 
the samples were obtained as a result of planned medi-
cal examinations of individuals with nosocomial HIV 
infection, during the period spanning 1991–2007. con-
sent letters were obtained from the parents of each of 
the examined children giving permission to use some of 
the samples obtained for research purposes. this sam-
ple of HIV-infected patients is unique, since there is 
no variability of infection development associated with 
differences in viral strains. All of the patients were in-
fected with the same viral strain (HIV-1 subtype G) 
originating from the original child that had been infect-
ed (focus nosocomial infection) [22, 23]. Furthermore, 
most patients belonged to two ethnic groups (russians 
and Kalmyks), thereby reducing the possible influence 
of genetic heterogeneity in each cohort. Anonymous 
data on patients’ birth dates and death dates in cases 
of fatal outcomes were obtained for 107 HIV-infect-
ed patients in the rostov district (all russians) and 60 
HIV-infected patients from elista (47 Kalmyks and 13 
russians). Blood samples of HIV-infected children (50 
russians and 27 Kalmyks, age varied from less than 1 
year to 16 years; median age 2.7 years) were used for 
the study. Blood samples taken from healthy volun-
teers were used as control samples. the first control 
group consisted of students of the rostov State Medical 
university (the majority of whom were born in 1986–
1990). According to the results of the survey, they were 
second-generation russians and were born in the ros-
tov district. the second control group consisted of Ka-
lmyks living in elista (ethnicity was established based 
on the survey results). Blood samples were collected in 
full compliance with the informed-consent procedure. 
the genetic study project obtained approval from the 
ethics committee of the Institute of the Institute of 
General Genetics, russian Academy of Sciences.
Genomic DnA was extracted from venous blood 
samples (up to 50 µl) using a commercial kit DnAPrep 
(IsoGene, russia) at the Biotechnology Laboratory of 
the Institute of Virology, russian Academy of Medical 
Sciences (equipped for handling infected samples), ac-
cording to the manufacturer’s procedure.
Genotyping was performed using Pcr amplification 
of DnA samples. the primers and amplification condi-
tions were described in [24]. Pcr products underwent 
2% agarose gel electrophoresis in order to determine 
the length of DnA fragments. 
Estimated value of the protective effect of 
CCR5del32 allele in the heterozygous state
the effects observed for all samples were uniformly 
characterized using the odds ratio measure (OR), which 
was calculated as the ratio between the chance of bear-
ing the wt/wt genotype in HIV-positive and HIV-neg-
ative individuals:
where P(*| HIV+) and P(*| HIV–) are the genotype fre-
quencies in the samples of infected and healthy indi-
viduals, respectively. the risk ratio (RR), which is de-
termined as the ratio between morbidities for various 
genotypes, was assessed using the following formula:
where Se is the test sensitivity for disposition, i.e., the 
frequency of the risk wt/ wt genotype in patients, and 
P(wt / wt) is the population frequency of the risk geno-
type.
the statistical significance of frequency differences 
was assessed using the two-tailed Fisher’s exact test.
the meta-analysis was conducted using a freeware 
package of statistical programs for epidemiologists 
WinPepi v.10 (2010) [25]. the package allows one to 
estimate the median OR value based on the fixed ef-
fects model (Mantel–Haenszel test) and the random ef-
fects model (Der Simonian–Laird method). the choice 
between the two models was made based on a dataset 
analysis (cochran’s Q test).
RESULTS
Allele and genotype frequencies in HIV-
infected patients and in the control groups
CCR5 genotyping was carried out for each child from 
the sample of children with nosocomial HIV infection 
and the control group individuals; CCR5del32 allele 
bearers were revealed (Table 1). Genotype distribution 
in all groups did not differ significantly from the Har-
dy–Weinberg equilibrium. the CCR5del32 allele fre-
quency was first ascertained in the Kalmyk population 
and was equal to 0.021 ± 0.012. the low allele frequency 
in the Kalmyk population correlates with its frequency 
in the neighboring population of the caucasus (3–5%) 
and the low frequency in the populations of central 
Asia of close origin with the Kalmyks (e.g., 1.1% for the 
Mongolians in china [26]). no bearers of this allele were 
detected in the sample consisting of 27 HIV-infected reSeArcH ArtIcLeS
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Kalmyk children (the differences from the frequency 
in the control group were insignificant: p = 0.558, based 
on the exact Fischer’s test).
According to the published data, the CCR5del32 al-
lele frequency in russians varies from 0.104 to 0.157 
(Table 2) (see review in [7]).the control group was 
formed of volunteers (the students of the rostov State 
Medical university) since most infected russian chil-
dren within the sample under study were undergoing 
treatment in rostov-on-Don hospitals; whereas the 
CCR5del32 allele frequency in russians of the rostov 
district was unknown. According to the survey results, 
they were second-generation russians and had been 
born in the rostov district. the CCR5del32 allele fre-
quency in this group was equal to 0.136 = 0.024, which 
lies within the frequency variability range in various 
geographic groups of russians. the CCR5del32 allele 
frequency in HIV-infected russian children turned 
out to be slightly lower (0.110 ± 0.031); however, the 
differences were of no significant degree (OR = 1.21, 
p = 0.69).
For such a small sample size, the lower CCR5del32 al-
lele frequency in HIV-infected individuals as compared 
with that in the control group may be a random effect 
or result from the protective action of this allele.
In a number of studies, data on the lower CCR5del32 
allele frequency and/or lower wt/del32 zygote fre-
quency among HIV-infected individuals as compared 
Table 1. Distribution of the genotype and allele frequencies over the CCR5 gene in HIV-infected children and in the 
control samples
Group n
number of 
individuals 
(genotype fre-
quencies, %)
Allele 
frequency 
and statistical 
error (±Se)
comparison 
of the HIV+ 
and control 
groups
wt/wt wt/del del/del wt del
HIV, Kalmyk children 27 27 0 0 1 0 Or = 2.85
p = 0.558
control, Kalmyks in 
elista 70 67 (95.71) 3 (4.28) 0 0.979 ± 0.012 0.021 ± 0.012
HIV, russian children 50 39 (78.0) 11 (22.0) 0 0.890 ± 0.031 0.110 ± 0.031 Or = 1.21
p = 0.690
control, russians in the 
rostov district 99 73 (73.7) 25 (25.3) 1 (1.0) 0.864 ± 0.024 0.136 ± 0.024
Table 2.The frequencies of the CCR5del32 (rs333) allele in groups of Russians and Kalmyks
Population n ccr5del32 allele 
frequency cI95% reference
russians: Leningrad district 33 0.166 0.083–0.300 [27]
Kostroma 54 0.157 0.091–0.252 [28]
St. Petersburg 50 0.130 0.069–0.223 [29]
Moscow 83 0.139 0.088–0.208 [30]
Moscow 176 0.122 0.088–0.164 [31]
ryazan 78 0.12 0.072–0.188 [32]
Lipetsk 48 0.104 0.045–0.192 M.M. Garaev’s own data
novosibirsk 53 0.104 0.051–0.187 [33]
Lys’va 186 0.100 0.070–0.138 [34]
Moscow, ethnicity not specified 171 0.091 0.062–0.129 [35]
rostov-on-Don 99 0.136 0.089–0.198 this study
russian children, HIV 50 0.110 0.054–0.198 this study
Kalmyks 70 0.021 0.004–0.063 this study
Kalmyk children, HIV 27 0 0–0.073 this study46 | ActA nAturAe |  VOL. 4  № 1 (12)  2012
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with the population control group have been obtained. 
In many cases, these differences do not reach any sig-
nificant level, whereas an opposite ratio between the 
frequencies has been revealed in some studies (Fig. 2 
and the database of allele frequencies (Genome Analy-
sis Laboratory, Institute of General Genetics, russian 
Academy of Sciences), http://vigg.ru/institute/po-
drazdelenija/otdel-genomiki-i-genetiki-cheloveka/
laboratorijaanaliza-genoma/allefdb/ccr5-hiv/). the 
meta-analysis of the published data was performed in 
the groups of HIV-infected patients and control groups 
in order to assess the eventuality of a protective effect 
of heterozygosity for CCR5del32.
Meta-analysis: does heterozygosity for 
CCR5del32 reduce the risk of infection?
For the meta-analysis, articles comparing the allele and 
genotype frequencies in the samples of HIV-infected 
patients and the corresponding control samples of unin-
fected individuals were selected from over 360 articles 
found in the PubMed database upon inquiry “ccr5 
AnD deletion AnD HIV” (September 2011). the pub-
lications studying Asian, African, and Latin American 
populations with aCCR5del32 allele frequency of 1–3% 
or lower were eliminated from the analysis.
As a result of the differences in the CCR5del32 al-
lele frequencies in populations of european origin (from 
5–8% in southern europe to 15–18% in northern eu-
rope) [7], the ethnicity of the control group individu-
als (and in some cases, their membership in subgroups 
within an ethnic group) has to closely match the eth-
nicity of the group of infected individuals. therefore, 
the publications in which the ethnicity of the groups 
was not indicated or the samples were not ethnically 
homogeneous were also eliminated. A total of 25 cau-
casian groups, including our sample, were selected for 
the meta-analysis: 5,967 HIV-infected individuals and 
5,410 control group individuals (Table 3).
the frequency of homozygous deletion bearers was 
4 of 5,967 HIV-infected individuals against 63 of 5,410 
individuals in the control group. this ratio corresponds 
to OR = 17.6 at p = 4.4 × 10–16. In this case, the rela-
tive risk value is approximately equal to the OR value; 
i.e., the infection probability of deletion homozygous 
individuals was lower than that of the bearers of the 
other genotypes by a factor of 17.6. close estimations of 
the protective effect of homozygocity for deletion were 
obtained in separate studies of euro-Americans, where 
the groups of seronegative individuals were compared 
with groups of seropositive individuals and the popu-
lation control groups [9, 38], and in some of the other 
studies [10, 11]. therefore, CCR5del32/ CCR5del32 ho-
mozygous individuals were eliminated from the subse-
quent analysis. the ratio between heterozygous bear-
ers of the CCR5del32 allele and the individuals without 
this allele (i.e., the ratio between the wt/CCR5del32 and 
wt/wt genotypes in the groups of HIV-infected indi-
viduals and the population control group) were consid-
ered to assess the risk of infection.
It was demonstrated via a comparison of the geno-
type frequencies that the frequency of wt/CCR5del32 
heterozygotes in HIV-infected individuals was higher 
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Fig. 2. Frequencies of heterozygous bearers of the 
CCR5del32 allele among HIV-infected (HIV+) and healthy 
(HIV–) individuals.1 – Belgians and French [10]; 2 – Swiss 
(HIV-infected [36], control group [37]); 3 – Euro-
Americans [38]; 4 – Danes [39]; 5 – Italians, Milan [40]; 
6 – Australians [41]; 7 – Finns [42]; 8 – Slovenians [43]; 
9 – Spaniards, Asturias [44]; 10 – Moscow residents 
[19]; 11 – Russians (HIV-infected – Muscovites, control 
– Russians, Ryazan) [20]; 12 – Spaniards, southern Spain 
[45]; 13 – Spaniards [46]; 14 – Hungarians [47]; 15 – Rus-
sians, Perm district [34]; 16 – Euro-American females [48]; 
17 – Germans, Munich [49]; 18 – Euro-Americans, Seattle 
[50]; 19 – Poles [51]; 20 – Italians [52]; 21 – Estonians 
[21]; 22 – Germans [13]; 23 – Slovaks [53]; 24 – Poles, 
Szczecin [54]; 25 – Russians, Rostov district (the present 
study).
Table 3. Mortality rate (by 2006) in the samples studied 
depending on genotype
Genotype russians Kalmyks
wt/wt 12 of 39 (30.8%) 11 of 27 (40.7%)
wt/del32 2 of 11 (18.2%) –
total 14 of 50 (28.0%) 11 of 27 (40.7%)reSeArcH ArtIcLeS
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than that in healthy individuals in only 4 out of 25 stud-
ies (Fig. 2). Based on the assumption that the effect was 
random, the probability of the event “the heterozygote 
frequency in affected individuals is higher than that in 
healthy ones in no more than 4 studies out of 25” was 
equal to 4.7 × 10–7 (similar to the probability of get-
ting no more than four heads after a coin is tossed 25 
times).
the odds ratio (OR) was determined for each sam-
ple; the OR values were then averaged with allowance 
made for the population size and degree of homogene-
ity of the effects. the results are presented in graphical 
form (Fig. 3).
It was found via a meta-analysis carried out on the 
basis of the results of 25 studies that the wt/CCR5del32 
heterozygote frequency against that of wt/wt homozy-
gotes in the samples of HIV-infected individuals was 
reliably lower than that in the control (p = 0.0002 with 
the two-tailed Fischer’s exact test and p = 0.00018 with 
the χ2 test). With the cochran’s Q test, heterogeneity 
of the data was insignificant: χ2 = 25.29,(p = 0.39).the 
variability fraction caused by the heterogeneity of OR 
values I2 = 5.1% (CI95% = 0–36.4%). this value is consid-
erably lower than the critical value (50%), which al-
lows one to use the “fixed effects model,” employing 
the Mantel–Haenszel test (MH average) for averaging 
the OR values. the total value of the effect is appreci-
ably low: OR = 1.22, CI95% = 1.10–1.36. However, these 
estimations have a large stability margin: 28 studies, in 
which the genotype frequencies would be the same for 
the samples of HIV-infected individuals and in the con-
trol group (OR = 1), need to be added to reduce the to-
Belgians, French [10]
Swiss [36, 37]
Euro-Americans [38]
Danes [39]
Italians [40]
Australians [41]
Finns [42]
Slovenians [43]
Spaniards [44]
Muscovites [19]
Russians [20]
Spaniards [45]
Spaniards [46]
Hungarians [47]
Russians [34]
Euro-American females [48]
Germans [49]
Euro-Americans [50]
Poles [51]
Italians [52]
Estonians [21]
Germans [13]
Slovaks [53]
Poles [54]
Russians, the present study
Average MH
0  1  2  3  4  5 
OR
Fig. 3. The estimated odds ratios (OR) 
and the corresponding 95% confidence 
intervals for 25 samples of Caucasians 
(specified in the legend to Fig. 2). The 
vertical dashed line corresponds to 
OR = 1 (no effects). The points on the 
right-hand side of this line indicate the 
protective effect of the wt/CCR5del32 
genotype. The size of the square markers 
is conventionally proportional to sample 
size. The lower diamond-shaped marker 
corresponds to the Mantel–Haenszel 
(MH) estimate of the averaged OR.48 | ActA nAturAe |  VOL. 4  № 1 (12)  2012
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tal value of the effect to an insignificant level OR = 1.
the possibility of publication bias is usually taken 
into account when performing a meta-analysis. the 
publication bias is a result of the fact that the research-
ers and journal editorial boards are more willing to 
publish positive rather than negative or “zero” results. 
Moreover, studies with significant effects obtained us-
ing small samples are often published. All of these facts 
may result in the overestimation of the averaged ef-
fect value in a meta-analysis (Fig. 4A). constructing the 
dependence of the effect value (OR) on sample size (a 
funnel plot) is the standard method for checking for 
data symmetry. A strongly asymmetric plot may attest 
to selective presentation of the data in publications. In 
our case, asymmetry is insignificant (Fig. 4B): the Ken-
dall rank correlation between OR and the sample size 
is equal to 0.21 at p = 0.187; asymmetry based on the 
regression test [55] is unreliable (p = 0.148).
thus, a statistically significant, although weak, pro-
tective effect of heterozygocity for the CCR5del32 al-
lele with respect to HIV-infected individuals (Or = 1.22 
at p = 2 × 10–4) was established by the meta-analysis, 
which included our own experimental data. An appre-
ciably low OR value explains the reason why no signifi-
cant differences in heterozygote frequencies between 
the HIV-infected individuals and those from the con-
trol groups have been found in the majority of articles. 
the data demonstrate that at a deletion allele frequen-
cy of 10% and OR = 1.22, the significant effect (p = 1.22 
at 80% strength) can be detected only when the total 
sample size is 4,500 (2,250 affected and 2,250 healthy 
individuals).
the estimated value OR = 1.22 does not mean that 
the risk of infection in the bearers of the wt/wt ho-
mozygous genotype is higher than that in the bear-
ers of the CCR5del32 allele by 22%. OR is the ratio be-
tween the chances, but not the risks of infection. the 
risk ratio parameter (RR), which is determined as the 
ratio between morbidities for various genotypes, can-
not be directly estimated in context-dependent case-
control studies. One may only propose various indirect 
estimations of rr based on OR and population allele 
frequency values or morbidity data [56]. Moreover, 
the inequality OR ≥ RR is always valid. According 
to the results of this meta-analysis, the correspond-
ing estimations are as follows: SE = 0.851 and P(wt/
wt) = 0.835; therefore, rr = 0.13. thus, the infection 
probability for wt/wt homozygous individuals is high-
er than that for the bearers of the CCR5del32 allele by 
at least 13%.
Our estimation is based on a comparison of the ratios 
between the wt/CCR5del32 and wt/wt genotype fre-
quencies in HIV-infected individuals and in the popula-
tion control group. It is evident that the HIV-infected 
individuals had contacted the virus and had been in-
fected; whereas the population control individuals had 
not contacted the virus (the fraction of the individu-
als who contacted the virus and/or HIV-infected ones 
is assumed to be negligibly small in the populations of 
european origin under study). the protective effect of 
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heterozygosity can be assessed more precisely by us-
ing the control group consisting of individuals who had 
contacted the virus but remained HIV-negative. How-
ever, the fraction of individuals in the existing high-
risk groups (haemophiliacs; sexual partners of HIV-in-
fected individuals; injection drug users; men practicing 
receptive penile–anal contacts with men (MSM); pros-
titutes) who had contacted the virus differs largely and 
sometimes cannot be determined. the random-effects 
model can be used when carrying out a meta-analysis 
of the results of these studies. However, because of the 
sample heterogeneity, OR estimations to a significant 
extent show the probability of contacting the virus in 
various risk groups rather than showing the direct pro-
tective effect of the allele in the group of individuals 
who contacted the virus.
this phenomenon can be illustrated by comparing 
the frequencies of homozygous genotypes for the de-
letion allele among uninfected individuals in two risk 
groups: haemophiliacs [57] and MSM individuals [38]. 
Among the uninfected individuals in the MSM group, 
the CCR5del32/del32 homozygote frequency was equal 
to 4.5% (5 of 11 individuals); whereas the frequency 
among the haemophiliacs was equal to 16.3% (7 of 43 in-
dividuals), given the fact that the population frequency 
of these homozygotes in the caucasian populations is 
less than 1–2%. the differences in the frequencies of 
individuals with homozygous deletion are statistically 
significant in the two risk groups (p = 0.038, two-tailed 
Fischer’s test). A higher CCR5del32/del32 homozygote 
frequency among haemophiliacs is accounted for by a 
higher risk of infection; for the individuals receiving in-
tense therapy with blood-based products in 1978–1985, 
it was equal to 94% [57]. Since almost 100% of patients 
who were administered blood-based samples contacted 
the virus, it can be assumed that the higher frequency 
of homozygotes for the deletion allele (i.e., a more pro-
nounced protective effect) cannot be achieved because 
of the genetic heterogeneity of the indicator of resist-
ance to infection with macrophagotropic HIV strains 
[58], similar to how the selection of protective alleles 
of different genes ensuring resistance to infection (e.g., 
malaria) is carried out in the same population under 
natural conditions.
Effect of heterozygosity for the CCR5del32 allele 
on the survival rate of HIV-infected individuals
the variability in the progression of the HIV infection 
into AIDS and the mortality rate were observed previ-
ously for both samples (for russians and Kalmyks). the 
variability is caused by nongenetic factors (infection 
age, which varies from several months to 14 years in 
these samples; the median age is 2.5 years), intensity of 
parenteral interventions, and concomitant diseases [3].
By 2006, the mortality rate in the sample studied 
was equal to 32.5% (25 of 77 individuals). the mortality 
rate was 28.0% (14 of 50) among the infected russian 
children and 40.7% (11 of 27), among Kalmyk children. 
By 2006, the rate of mortality in russians in the studied 
group was lower than that for the Kalmyks by 31.2%; 
however, these differences were insignificant for the 
given sample sizes (p = 0.311). nevertheless, the regres-
sions describing the general mortality dynamics differ 
to a significant degree: the slope angle of the regression 
for russian children is equal to –0.016 ± 0.004, against 
–0.025 ± 0.002 for Kalmyk children (p = 0.02, two-tailed 
Z test).
the effect of the carriage of the CCR5del32 allele on 
the survival rate of infected individuals was tested, as 
well as whether the differences in longevity post-infec-
tion could be linked to the differences in the CCR5del32 
frequency in the two ethnic groups.
In the sample subjected to study, no deletion allele 
was detected in HIV-infected Kalmyk children; all of 
them had the wt/wt genotype. Among the infected 
russian children with the wt/wt genotype, the rate 
of mortality was 30.8% (12 of 39%), and 18.2% (2 of 11) 
among the bearers of the ccr5del32 allele (Table 3). 
thus, the mortality rate in russian children with the 
wt/CCR5del32 genotype 15 years after the infection 
was lower by 40.9% compared with that of the children 
without the deletion allele, although these differences 
are statistically insignificant (OR = 2.0; p = 0.705). the 
limited sample size makes it impossible to accept or re-
fute the hypothesis that the differences in longevity 
in the two ethnic groups are caused by the differences 
in the CCR5del32 allele frequencies. nevertheless, it 
should be noted that our insignificant estimations lit-
erally line up with previously published data. Accord-
ing to the results of the meta-analysis of 19 cohorts of 
HIV-infected individuals (a total of 1,635 caucasians), 
the protective effect of heterozygous bearing of the 
CCR5del32 allele manifested itself in a 39% decrease in 
the risk of death [17]. In order to attain statistical sig-
nificance at this level of the effect (OR = 2), the sample 
size for the infected individuals has to be at least 550 
individuals at a mortality rate of 30% and 400 people at 
the instant when mortality is as high as 60%.
thus, in the study that focused on 507 HIV-infect-
ed Poles who were observed over a period of 15 years 
prior to the introduction of antiretroviral therapy, the 
differences in the rate of mortality between the bear-
ers of the wt/del32 and wt/wt genotypes were equal 
to 49% (the overall mortality rate being 19%). these 
differences were statistically significant (p = 0.026), 
whereas the differences were insignificant (p = 0.23) 
for individuals receiving treatment (442 individuals) 
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DISCUSSION
the  effect  of  the  heterozygous  bearing  of  the 
CCR5del32 deletion allele on the risk of HIV infection in 
populations of european origin (without allowance for 
the route of infection transmission, viral serotype, and 
differences in antiretroviral therapy) was first assessed 
based on the meta-analysis of published data. the pro-
tective effect observed was rather small (OR = 1.22) 
but was statistically significant and corresponded to a 
decrease of at least 13% in the risk of infection in the in-
dividuals with the CCR5wt/del32 genotype, according 
to the calculations. the small OR value explains why 
the differences between the frequencies of genotypes 
and/or ccr5del32 allele between the groups of HIV-
infected individuals and the control group detected in 
most articles are statistically insignificant.
the size of the samples that are to be studied in or-
der to demonstrate the reliability of this phenomenon 
reversely depends on the allelic abundance in the popu-
lation. In particular, in chinese populations, where the 
abundance of the CCR5del32 allele is lower than that 
in europeans, no significant protective effect of het-
erozygous bearing of wt/del32 has been detected via a 
meta-analysis: OR = 1.156 (CI95% = 0.808–1.654) [60].
the CCR5del32 allele is predominantly present in 
populations of european origin; its abundance in south-
ern european population groups (Spaniards, Italians, 
and Greeks) is equal to 5–8%, being as high as 15–18% 
in northern european population groups (Finns, estoni-
ans, Mordvinians, tatars, etc.) [7]. In russians, the fre-
quency of the CCR5del32 allele is appreciably high (10–
17% in different regions), whereas the frequency of this 
allele is equal to 2% in the other group that was studied 
(Kalmyks). can the differences in the frequency of the 
protective CCR5del32 allele play a substantial role in 
the prevention of the HIV infection at the population 
level or can they be accounted for by the differences in 
the mortality rate of HIV-infected individuals?
Hypothetically, the population effects caused by the 
presence of the deletion allele can be assessed as fol-
lows. Let us assume q to be the frequency of the dele-
tion allele, and Sww, Swd, and Sdd – the survival rates of 
the infected individuals with wt/wt, wt/CCR5del32, or 
CCR5del32/CCR5del32 genotypes, respectively. then, 
the population average survival rate Spop is higher than 
the survival rate of the individuals with the wt/wt 
genotype by the following figure:
ΔS = Spop – Sww = (1–q)2Sww + 
+ 2q(1–q)Swd+ q2Sdd – Sww ≈ 2(Swd – Sww)q.
the terms of q2 order were neglected in the latter 
equality. thus, the protective effect of heterozygous 
bearing of the CCR5del32 allele (a 40% decrease in the 
mortality rate for the infected individuals) for a 10% 
frequency of this allele provides an 8% decrease in the 
general death rate for the HIV-infected individuals 
against the group without bearers of this allele. A de-
crease in the risk of infection due to the presence of 
the CCR5del32 allele in the population is calculated 
identically. If the probability of infection of hetero-
zygous individuals is reduced by 13%, the general in-
fection frequency for the population is reduced by 
3.3%. At a 15% allele frequency, the decrease in the 
infection rate would be 5.6%; whereas the decrease 
in the mortality rate of the HIV-infected individuals 
would be 12%.
to summarize, protection against the HIV infection 
and the reduction in mortality rates in HIV-infected 
individuals at the population level is rather small even 
in groups with a high frequency of the CCR5del32 al-
lele (15%). In addition to CCR5del32, there are other 
genes which affect both the susceptibility to HIV in-
fection and the course of progression of the HIV infec-
tion [61] and have the ability to contribute to inter-
population differences. thus, russians and Kalmyks 
differ in terms of the frequencies of the protective 
C/C genotype at polymorphism in the regulatory site 
of the interleukine 10 gene IL10–592 A/c (49%in rus-
sians in the rostov district and 33% in Kalmyks in elis-
ta) and in terms of the frequencies of the protective 
ccr2-64I allele (12% in russians of the rostov district 
and 23% in Kalmyks in elista) (the data obtained by 
the authors have yet to be published). However, the 
possible contribution of these genes to interpopulation 
differences in the progression of the HIV infection re-
quires further studies. the authors express the hope 
that samples with nosocomial infections will no longer 
be available. 
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